Stockreport

PAVmed FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]

PAVmed Inc.  (PAVM) 
US:NASDAQ Investor Relations: ir.pavm.com
PDF SummaryPAVmed's carpal tunnel syndrome device CarpX is approved.Prothena's Parkinson's study flops, taking the stock down.Mallinckrodt's kidney failure drug application [Read more]